NCT06912490 Proteomic Analysis of Amniotic Fluid to Predict Postnatal Renal Function in Fetuses With Renal and Urinary Tract Malformations
| NCT ID | NCT06912490 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Toulouse |
| Condition | Kidney Diseases |
| Study Type | INTERVENTIONAL |
| Enrollment | 78 participants |
| Start Date | 2025-07-18 |
| Primary Completion | 2029-12-20 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 78 participants in total. It began in 2025-07-18 with a primary completion date of 2029-12-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this project is to validate a previously established amniotic fluid 98 peptide signature predictive of post-natal outcome in fetuses with congenital anomalies of the kidney and the urinary tract (CAKUT) in a "real" clinical context. It includes the feasibility of collecting, transporting and analyzing the amniotic fluid peptidome from clinical centers all over France and of providing the result in a clinically accepted time-frame. Therefore, this multicenter study will not only allow to determine the added value of such new prenatal test but also to ensure the feasibility of its introduction in the management of CAKUT pregnancies.
Eligibility Criteria
Inclusion Criteria: * All fetuses with bilateral renal development anomalies with structural changes in the parenchyma, with or without associated urinary tract anomalies; * Signed informed consent of the mother * Non-opposition of the father. Exclusion Criteria: * Unilateral abnormality of renal development * Any pregnancy for which amniocentesis may represent a risk for the fetus or the mother * Twin pregnancies * Pregnant woman protected by law (guardianship, curatorship)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06912490 clinical trial?
This trial is open to female participants only, studying Kidney Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06912490 currently recruiting?
Yes, NCT06912490 is actively recruiting participants. Contact the research team at simon.t@chu-toulouse.fr for enrollment information.
Where is the NCT06912490 trial being conducted?
This trial is being conducted at Toulouse, France.
Who is sponsoring the NCT06912490 clinical trial?
NCT06912490 is sponsored by University Hospital, Toulouse. The trial plans to enroll 78 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.